Table 3.

Clinical outcomes by study phase.

			Intervention group		Standard-of-Care groups
	Total (N=908)		Clinic-based testing (N=222)		Clinician-directed testing (N=323)			Lab reflex testing (N=363)
Post-baseline clinical outcomes	n	% (CI)	n	% (CI)	n	% (CI)	p*	n	% (CI)	p*
Primary outcomes
Cryptococcal meningitis diagnosis	30	3.3 (2.3–4.7)	10	4.5 (2.4–8.2)	5	1.5 (0.6–3.7)	0.059	15	4.1 (2.5–6.8)	0.836
All-cause hospitalization	98	10.8 (8.9–13.0)	21	9.5 (9.5–14.1)	28	8.7 (6.0–12.3)	0.762	49	13.5 (10.3–17.4)	0.151
All-cause mortality	85	9.4 (7.6–11.4)	18	8.1 (5.1–12.5)	31	9.6 (6.8–13.3)	0.648	36	9.9 (7.2–13.5)	0.557
Secondary outcomes
Hospitalization due to known cryptococcal infection	11	1.2 (0.7–2.2)	4	1.8 (0.5–4.7)	4	1.2 (0.4–3.3)	0.721	3	0.8 (0.2–2.5)	0.436
Mortality due to known cryptococcal infection	9	1.0 (0.5–1.9)	4	1.8 (0.5–4.7)	1	0.3 (0.0–1.9)	0.164	4	1.1 (0.3–2.9)	0.486
Initiation of antiretroviral therapy	850	93.6 (91.8–95.0)	215	96.8 (93.5–98.6)	295	91.3 (87.7–94.0)	0.012	340	93.7 (90.6–95.8)	0.121
Received fluconazole preventative therapy**	46	5.1 (3.8–6.7)	16	7.2 (4.4–11.5)	8	2.5 (1.2–4.9)	0.010	22	6.1 (4.0–9.1)	0.607
Received intravenous amphotericin-B	8	0.9 (0.9–3.1)	3	1.4 (0.3–4.1)	4	1.2 (0.4–3.3)	1.000	1	0.3 (0.0–1.7)	0.156
Lost to follow-up	113	12.4 (10.5–14.8)	16	7.2 (4.4–11.5)	56	17.3 (13.6–21.9)	0.001	41	11.3 (8.4–15.0)	0.116

CI: 95% confidence interval.

^*p-value represents a Fisher’s exact test of the comparison between each standard of care group with the Intervention group.

^**Oral fluconazole was indicated for people with serum cryptococcal antigenemia, but without cryptococcal meningitis.